Chemkart India is evolving from a B2B nutraceutical distributor to a high-margin CDMO player, backed by strong industry tailwinds and strategic execution.
- Positioned to benefit from India’s $76B nutraceutical opportunity
- Building a greenfield SEZ manufacturing facility with advanced technologies
- Strong financial track record: 32% revenue CAGR | 64% PAT CAGR
- Targeting ₹450 Cr revenue by FY28
- Valuation upside of ~170% with a BUY call
The growth story is driven by backward integration, global expansion, and innovation-led manufacturing.
Detailed Analysis in the coverage report

